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2Abstract
A combined approach based on two dimensional electrophoresis-immuno blotting and
nanoliquid chromatography coupled on-line with electrospray ionization mass
spectrometry (nLC-MS/MS) was used to identify proteins modified by a reactive
intermediate of tienilic acid (TA). Liver homogenates from rats exposed to TA were
fractionated using ultra centrifugation; four fractions were obtained and subjected to 2D
electrophoresis. After transfer to PVDF membranes, modified proteins were visualized
after India ink staining, using an anti-serum raised against TA and ECL detection.
Immuno-reactive spots were localized on the PVDF membrane by superposition of the
ECL image, protein spots of interest were excised, digested on the membrane with
trypsin followed by nLC-MS/MS analysis and protein identification. A total of fifteen
proteins were identified as likely targets modified by a TA reactive metabolite. These
include selenium binding protein 2, senescence marker protein SMP-30, adenosine
kinase, Acy1 protein, adenosylhomocysteinase, capping protein (actin filament), protein
disulfide isomerise, fumarylacetoacetase, arginase chain A, ketohexokinase, proteasome
endopeptidase complex, triosephophate isomerase, superoxide dismutase, dna-type
molecular chaperone hsc73 and malate dehydrogenase.
Keywords. 2D immuno blotting, tienilic acid, nanoliquid chromatography-electrospray
ionization mass spectrometry, on-membrane digestion, protein modification.
31.0 Introduction
Drug induced autoimmune hepatitis, characterized by hepatitic, cholestatic, or
miscellaneous clinical features belongs to some of the most severe adverse drug
reactions. Common to these reactions are the involvement of an improper immune
response that is directed toward the host’s liver. Studies in the past indicate that the
uricosuric diuretic agent, tienilic acid (also named, Ticrynafen, Selacryn, Diflurex; 2,3-
dichloro-4-(2-thienylcarbonyl) phenoxyacetic acid) (TA) causes drug induced-
autoimmune hepatitis in certain persons. As a consequence, TA was withdrawn from
clinical use in the United States in the early eighties [1] and in France in 1992. Although
several mechanisms may be involved, the current understanding of drug induced-
autoimmune diseases is based on two interdependent complementary working hypotheses
e.g. the “Hapten” and the “Danger” hypothesis [2-4]. Of importance for both hypotheses
is the requirement for metabolic transformation of the drug to a reactive metabolite(s),
resulting in two different but essential outcomes. The first involves covalent modification
of cellular macromolecules by reactive metabolites that after intra cellular processing
lead to modified peptides being presented as antigens to the immune system, probably via
the MHC processing system. In addition, it seems likely that in order to trigger the
immune response some kind of cellular stress should be present. This assumption is based
on the fact that immune mediated adverse drug reactions are dramatically increased in
persons concomitantly infected with a virus or suffering from other ailments [5].
Metabolic activation of a drug causing either direct or indirect up-regulation of cellular
stress proteins could be involved. Alternatively, modification of essential or specific
stress proteins could be an important factor resulting in cellular stress. Initial phases of
4TA toxicity are believed to be due to metabolic activation by CYP450 2C9 to a reactive
metabolite that can deplete glutathione (GSH) and covalently bind to certain proteins.
Analysis of sera obtained from patients suffering from liver damage following TA
exposure revealed the presence of highly specific anti-liver and kidney microsomal (anti-
LKM2) autoantibodies [6] known to specifically recognize CYP450 2C9 in humans [7,8]
and the corresponding isoform 2C11 in rats[9]. Subsequent studies have revealed that
tienilic acid undergoes a selective CYP450 2C9-mediated bioactivation on its thiophene
ring, resulting in the formation of a reactive intermediate that covalently modifies the
enzyme [10] despite that a stable peptide conjugate has never characterized [11,12]. A
relatively limited number of proteins appear to be modified by TA metabolites in both
human and rat liver microsomes [9,10,13,14]. In contrast, the isomer of TA has been
shown to be metabolized into a thiophene sulfoxide, leading to modification of many
more proteins [9,15,16]. In addition, TA could be metabolized by other until now
unknown or known enzymes without suicide inactivation resulting in protein
modification but this has yet to be confirmed. For a number of carboxylic acid containing
drugs, glucuronidation has been proposed to be a major metabolic pathway that
potentially could increase the reactivity of certain drugs resulting in covalent
modification of proteins [17]. The formation of reactive metabolites by this pathway and
covalent protein modification has previously been demonstrated for numerous non
steroidal anti-inflammatory drugs including ibuprofen [18], ketoprofen [19] and
zomepirac [20] as well as for other drugs like mycophenolic acid [21], clofibric acid [20],
diflunisal [22,23] and valproic acid [20]. Despite that proteins have been found to be
covalently modified by reactive drug metabolites both in vivo and in vitro, only a
5relatively small number have until know been identified. So far, proteomics approaches
based on mass spectrometry and separation techniques suitable for this type of analysis,
have only been used in a few cases [21,24,25]. Recently, we developed a new approach
allowing the mass spectrometric analysis of immuno-reactive protein spots obtained from
the membrane used for Western blotting and thus to identify post translationally modified
proteins including those modified by reactive drug metabolites [26]. Except for CYP
P450 2C9 and the 2C11 variant in rats, a comprehensive knowledge about what cellular
proteins are covalently modified after exposure to TA is still lacking. The aim of the
present study was to take advantage of a proteome approach exploiting pre-fractionation
of cellular organelles and 2D Western blotting in combination with mass spectrometry to
identify the comprehensive suite of modified rat liver proteins.
2.0 Experimental
2.1 Animals and sample preparation
The experimental protocol was approved by the institution animal care unit. Wistar rats
(~200-250 g) were allowed to rest for one week before exposure to TA. Rats having
received an injection intra-peritoneal of TA (100 mg of drug per kg of weight) or saline
(control) were sacrificed at 4 and 24 hours respectively. The livers were immediately
removed, sliced into small pieces with a clean scalpel and homogenized at 4ϒC in 7 ml of
buffer (10mM Tris-HCl pH 7.5, 250 mM sucrose, 20 µl peptidase inhibitor cocktail)
using a potter helm homogenizer with a loose pestle and 5-10 strokes per 1g of liver.
These procedures were repeated in two independent experiments.
2.2 Enrichment of liver sub-cellular fractions by ultra-centrifugation.
6Rat liver homogenate was centrifuged at 600 x g for 10 min to precipitate cell nuclei and
cellular debris.   The supernatant was collected, transferred into ultracentrifuge tubes and
further centrifuged at 15.000 x g for 5 min. The precipitate represented fraction I.
Centrifugation of the supernatant at 100.000 x g for 60 min resulted in fraction II. The
last ultracentrifugation at 100.000 x g for 5 hours gave fraction III (precipitate) and
fraction IV (supernatant).  Centrifugations were performed at 4 ϒC using a Sorvall RC 5B
plus centrifuge (Mandel, ON, Canada) and the enriched sub-cellular fractions were stored
at -20ϒC until further analysis. Protein concentrations in each step were estimated using
the BCA assay (Pierce, Rockford, IL, US). Samples were dissolved in 10% SDS and
dilutions were made in 1% SDS prior to performing the assay as described by the
manufacture.
2.3 2D Electrophoresis and protein staining.
Protein 2D SDS-PAGE separations were performed in the first dimension by isoelectric
focusing (IEF), using ReadyStrips (pH 3-10, 4–7 and 5.5-6.7, 11 cm long, Bio-Rad,
Mississauga, ON, Canada). The ReadyStrips were  rehydrated overnight at room
temperature in 185 µl of sample buffer (7M urea, 2M thiourea, 4% CHAPS, 100mM
dithiothreitol, 1:50 volume of Biolyte pH 3-10, and a trace of bromophenol blue)
containing 400 µg of protein. The IEF was performed using a PROTEAN IEF Cell
system (Bio-Rad) at 20°C with the following voltage gradient: 250 V over 20 min,
250–8000 V over 2.5 h, and then 8000 V until 20 kVh was attained. After IEF, proteins
were reduced for 10 min in equilibration buffer (50 mM Tris-HCl pH 8.8 containing 6 M
urea, 30% glycerol and 2% SDS, 100mM DTT) and alkylated for 10 min in the dark with
iodoacetamide (25 mg/ml) in the same buffer but without DTT.  Proteins were then
separated by SDS-PAGE according to the method of Laemmli {Laemmli, 1970 #197}
7using 8-16% polyacrylamide gradient gels, for 150 min at 50 mA/gel.  The gels were
processed for Western blotting by transferring the proteins onto a PVDF membrane using
a Trans-Blot SD semi-dry transfer cell (Bio-Rad, Mississauga, ON, Canada) for 55 min at
0.8 mA/cm2 as described elsewhere {Mengue Methogo, 2005 #181}.
2.4 Immuno chemical detection.
PVDF membranes were rinsed after electroblotting for 5 min first in 20% MeOH and
then in water prior to blocking for 10 min in 0.1% aqueous acetic acid containing 0.2%
Tween 20. The proteins were stained in PBS containing 0.05% (v/v) Tween 20, 1% (v/v)
acetic acid, and 0.1% (v/v) Fount India ink until visible bands appeared (30 min to 12h).
The PVDF membrane was then rinsed in wash buffer (150 mM NaCl, 10 mM Tris-HCl
pH 7.6, 0.05% Tween 20) and incubated overnight with the primary antiserum raised
against TA (diluted 10.000x) in wash buffer. The antiserum was raised against BSA
coupled to 5-chloro TA after activation of lysine residues with N-succinimidyl 3-(2-
pyridyldithio)-propionate, prepared as described previously {Bonierbale, 1999 #196}.
The anti-serum specificity was evaluated using competitive inhibition ELISA, _-
lactoglobulin coupled as described for BSA and serial dilutions of TA, TA conjugated
with mercaptoethanol, ethacrynic acid, 2-,3-dichlorophenoxy acetic acid and TA-isomer
{Bonierbale, 1999 #196}. Following incubation with primary anti-serum, the PVDF
membrane was washed 4 x 5 min in wash buffer before incubation for 1h with monkey
anti-rabbit IgG antibody (diluted 100.000x in wash buffer) conjugated with horseradish
peroxidase.  Following 4 x 5 min wash of the membrane in wash buffer, the ECL was
developed as described by the manufacture for 1-2 min. In order to identify immuno-
reactive protein spots on the PVDF membrane, the transparency obtained after ECL
8detection was positioned on the membrane and pierced with a needle through the dark
ECL spots leaving marks at the exact position. Membrane spots were then excised with a
sharpened stainless steel tube and stored in Eppendorf tubes at -20 °C until further use.
2.5 On-membrane digestion.
On membrane proteolysis was performed as previously described {Mengue Methogo,
2005 #181} except for following modifications: After reduction and alkylation with
iodoacetamide membrane pieces were rinsed 4x with 400 µl 50% ACN in 100 mM
ammonium bicarbonate buffer (ABC) which was found to efficiently diminish tween-20
contaminants resulting in cleaner nLC-MS analyses. The solvent used for digestion
consisted of 100 mM ABC with 50% (v/v) anhydrous amine free N,N-
dimethylformamide (Alfa Cesar, MA, US) and was prepared immediately before use. In
brief, prior to digestion proteins were reduced in 20 ul of 100 mM ABC containing 5
_g/_l DTT for 45 min at 37 °C. Carbamidomethylation was carried out in 20 _l of 200
mM ABC containing 25 _g/_l iodoacetamide for 30 min in the dark. Following rinsing as
described above, proteins were digested at 37 °C in 10 _l 50 mM ABC containing 50%
(v/v) DMF and 20 ng/_l sequencing grade trypsin (Promega, USA) with occasional
centrifugation to avoid concentration of DMF in the proteolysis buffer. After 3 h and the
addition of 1 ul of 5 M urea, samples were incubated in an ultrasound bath for 2 min,
transferred to injection vials and dried in an Eppendorf Vacufuge Concentrator until
completely dry (about 1 h).
2.6 NanoLiquid chromatography-tandem mass spectrometry and data base
searching.
9 Peptides derived from “on-membrane” digestion were analyzed by nanoliquid
chromatography coupled on-line with tandem electrospray ionization time-of-flight mass
spectrometry (nLC-ESIMS/MS) consisting of a capillary liquid chromatograph with
autosampler and a QTOF 2E mass spectrometer (Waters, MA, US). Tryptic peptides
were dissolved in 14 µl solvent A (1% acetonitrile, 1% isopropanol in 0.2% aqueous
formic acid), loaded onto a 0.5 mm x 250 µm I.D union packed with Magic C18 AQ(200
A, 5 µm; Michrom BioResources, Auburn, CA) and separated on a 100 µm I.D x 10 cm
capillary column packed with the same material. Each analysis was succeeded by
injection of 10 µl 50% (v/v) aqueous isopropanol followed by running a blank gradient,
which efficiently eliminated contamination from sample carry over. The following linear
gradient was used: from 10 to 70% B in 30 min, to 90% B in 5 min, and 10% B in 3 min.
The flow rate was split approximately 10x to 0.25-0.30 µl/min. Survey scans were
acquired at 1.9 s/scan. Depending on the charge state and intensity, doubly and triply
charged parent ions were automatically selected for tandem mass spectrometry acquired
at 1 s/scan with a pre-set maximum of 5 scans per selected parent ion. Since singly
charged parent ions were not selected for tandem mass spectrometry, the intensity
threshold could be lowered to a minimum without the risk of spending acquisition time
on ions from background, impurities and detergents. Although a low threshold is not a
guaranty of acquiring MS/MS spectra useful for protein identification, it ensure selection
of a maximum number of doubly and triply charged ions for MS/MS analysis, during the
separation. Raw MS/MS spectra were processed automatically using the ProteinLynx
software and converted into peak lists readable by the MASCOT search algorithm
(http://www.matrixscience.com). The following search parameters were used: database;
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MSDB, species; Rattus, allowance of two missed tryptic cleavages, oxidation of
methionine and cysteine carbamidomethylation, fragment mass tolerance; 0.25 Da.
3.0 Results
To achieve a survey and identify the suite of rat liver proteins modified by TA
metabolites, rats were treated with either saline (control) or TA (100 mg/kg). After time
intervals of 4 and 24 hours, the liver was isolated, homogenized and proteins were
separated by 2D SDS PAGE. In preliminary experiments, proteins from total liver
homogenates were focused in the first dimension from pH 3-10 followed by separation in
the second dimension on gradient polyacrylamide gels. Proteins modified covalently by
TA metabolites were visualized on the corresponding Western blots with a polyclonal
antiserum to TA [9]. A maximum of approximately 20 spots appeared to contain
modified proteins, as judged by their immuno-reactivity. The spots were absent on
Western blots of the control and appeared to increase in number from 4 to 24 h in two
independent experiments. Although, it could not be entirely excluded that the increased
intensity are due to variations in the sample amounts loaded onto the gels, the absence of
immuno reactive spots in the control lead us to conclude that the immuno-reactivity was
not due to non-specific cross reactivity of the antiserum (Figure 1). As the ECL images
were very similar but the number of immuno-reactive spots was increased at 24 h, we
decided to pursue the subsequent analyses using the liver recovered from this rat. All of
the immuno-reactive spots were estimated to be within the isoelectric point range 5-7.
This was further confirmed by 2D Western blotting of total liver homogenate after
isoelectric focusing on 4-7 IPG strips (data not shown). Preliminary attempts to identify
the modified proteins using on-membrane digestion, nLC-ESIMS/MS and data base
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searching turned out to be complicated by the fact that the protein spots were highly
heterogeneous because of incomplete protein separation (data not shown). Therefore, to
improve the electrophoretic separation of the proteins and to increase the likelihood of
detecting most proteins potentially adducted with TA, we took advantage of two sample
purification steps. Firstly, total liver homogenates were subjected to rough pre-fractioning
with ultra-centrifugation. This step resulted in four major fractions (I-IV). Secondly, the
proteins were separated in the first dimension using IPG strips with a narrow pH range.
An overview of the strategy used throughout this work is shown in figure 2. The four
fractions, obtained after ultracentrifugation were subjected to isoelectric focusing using
5.5-6.7 immobiline strips, and subsequently proteins were resolved on 8-16% mini
gradient gels. Following blotting onto PVDF membranes, TA adducted proteins were
visualized by ECL as shown in figure 3. Comparison of the ECL revealed relatively
similar images for the fractions with several overlapping spots. This indicates that either
the immuno-reactive proteins are dispersed in several cellular locations and/or the
separation capacity of ultracentrifugation, as expected, could be limited.  The number of
most abundant and reproducibly detected immuno-reactive spots in the four fractions
ranged from 24 (fraction I), 24 (fraction II), 5 (fraction III) to 13 spots in fraction IV,
with the latter enriched in soluble cytosolic proteins. No spots were observed on the
corresponding control Western blots using fractionated liver homogenate from rats
treated with saline (data not shown). Immuno-reactive spots from each fraction were
excised from India ink stained PVDF membranes used for the Western blotting
experiments and subsequently subjected to reduction, carbamidomethylation and on-
membrane proteolysis with trypsin. The recovered peptides were analyzed by nLC-
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MS/MS and corresponding proteins were identified in the Rattus protein data base using
MASCOT. A total of 66 protein spots were analyzed, all resulting in positive protein
identifications despite that most of the spots were not detectable by the India ink stain.
An example of nLC-MS/MS analysis of tryptic peptides from spot 14, ultra
centrifugation fraction II (Figure 3C,D and table II), is shown in figure 4. A flat HPLC
gradient was used to insure sufficient time to produce tandem mass spectra of all doubly
and triply charged ions with intensities above background level. Nine of the peptide ions
selected for tandem mass spectrometry gave adequate spectra that could be
unambiguously assigned to the iota chain of proteasome endopeptidase complex (EC
3.4.25.1). The results of all protein identifications are shown in table I-IV. As can be
observed in table I-IV numerous spots contained multiple proteins compromising our
ability to unambiguously identify certain modified proteins. Fortunately, the same protein
could be identified in multiple immuno-reactive spots helping to pin-point which protein
was modified among several co-migrating proteins. The presence of a common modified
protein in multiple spots, although heterogeneous, explained the immuno-reactivity. The
reasons for dispersion of proteins to more than one 2D spot are multifarious including
different degrees of post translational modifications like phosphorylation, presence of
various isoforms and the presence of fragments due to incomplete inactivation of all
proteases in the cell lysate.  Furthermore, many of the proteins suggested to be modified
were observed in more than one Western blot of individual ultracentrifugation fractions
and co-migrated with different proteins. Since the immuno-reactivity of the spots was
maintained, this confirmed their assignment as modified proteins. For example,
adenosylhomocysteinase could be identified in three out of the four fractions. In fraction
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II (table II), adenosylhomocysteinase in spot 11 co migrated with a TAR DNA binding
protein. However, adenosylhomocysteinase was also identified in fraction III (spot 4,
table III) although it co-migrated here with alpha enolase and methionine adenosyl
transferase. Finally, adenosylcysteinase was identified in three distinct immuno-reactive
spots (10, 11 and 12) obtained from the PVDF membrane used for ECL detection of
fraction IV (Figure 3).  In these three spots, adenosylhomocysteinase co-migrated with
one, two and five other proteins. Obviously, it cannot be ruled out that several immuno-
reactive proteins co-migrated as shown in Fraction IV spot 12, which compromised the
assignment of the immuno-reactivity. Six proteins were identified in spot 12 with 3 to 22
assigned tandem mass spectra and total Mowse scores ranging from 62 to 452. Since
fumarylacetoacetase was identified unaccompanied in spot 13 and is present in spot 12,
together with adenosylhomocysteinase it may be a candidate for the immuno-reactivity.
Although it cannot be excluded, it is uncertain as to whether beta-alanine synthethase and
4-hydroxyphenylpyruvate dioxygenase are candidates because they constantly co-
migrated with other highly potential immuno-reactive candidates (Table I, spot 9 and 10,
Table II, spot 17, Table IV spot 11 and 12). Interpretation of collective data from the
analyses of four fractions using the procedure described above resulted in a list of 15
candidate proteins shown in Table V that are likely to be modified by TA metabolites.
Although rat albumin was found in most of the fractions and was identified in several of
the spots, these analyses did not allow us to unambiguously conclude that rat albumin is
modified by TA metabolites because the antiserum was raised against bovine albumin-
TA conjugates. However, the absence of spots corresponding to rat albumin on control
Western blots indicates that, if present, cross reactivity is limited. Furthermore, keratins
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can easily contaminate carrier protein drug metabolite preparations. In both cases, antigen
cross reactivity could not be completely eliminated, and thus these proteins were not
included in table V.
4.0 Discussion
In the present work, we demonstrate that 2D Western blotting in direct conjunction with
nLC-MS/MS can be used to identify rat liver proteins that are highly likely to be
covalently modified by TA metabolites. Previously, the identification of proteins
modified by drug metabolites using Western blotting was limited to in gel digestion of
the proteins of interest after localisation of the spots on a 2D SDS PAGE gel using an
ECL image obtained from immuno-blotting of a parallel gel. This method is useful when
immuno-reactive proteins can be observed with mass spectrometry compatible gel
staining methods. However, in our hands, this is not always the case rendering the
location of the immuno-reactive spots very difficult due to the extensive discrepancy of
ECL and gel staining images. In contrast, our method takes advantage of the fact that
after on-membrane proteolysis it is possible to recover sufficient amount of peptides from
the India ink stained PVDF membrane used for immuno-blotting to subsequently acquire
high quality nLC-MS/MS data. Furthermore, the facility and precision by which the
protein spots can be located on the PVDF membrane after superposition of the ECL
image insure that the correct immuno-reactive spot is excised and the method is therefore
likely to diminish faulty protein identifications. Considering the frequently high
sensitivity of immuno-blotting one can not exclude that, from a mass spectrometry point
of view, undetectable lower levels of immuno-reactive proteins could be present. The
sensitivity of the method depends on the mass spectrometer used for analyses. With the
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instrument used in this study, the lower limit of detection was estimated from injecting a
standard peptide mixture to be about 25-50 femtomol per peptide in order to obtain
adequate tandem mass spectra for protein identification. Of notice, the protein amount
retained on the PVDF membrane of several immuno-reactive protein spots was
insufficient for visualization by India ink staining. Although this compromised the choice
of an appropriate spot size to excise, the dimension of our spot picking tool corresponded
well to the vast majority of spots observed on the ECL transparency. Nevertheless, it can
obviously not be excluded that some of the protein heterogeneity could be due to excision
of closely located neighbouring proteins. Despite that relatively few immuno-reactive
spots were homogenous, the occurrence of protein isomers in several spots from identical
fractions and their co-migration with different proteins in other fractions aided in
determining which proteins may be responsible for the immuno-reactivity observed by
ECL. Optimal separation can be obtained with longer immobiline strips and larger 2D
gels, however, at the expense of a larger consumption of antibodies and ECL reagents.
Furthermore, larger gels are in general more fragile and difficult to handle for the purpose
of immuno blotting. In light of these considerations, we chose to use a medium size gel
(10 x 10 cm) compromising to some extend the protein separation. Attempts to determine
which peptides, site and type of covalent modification(s) using the GPM search engine
(http://rat.thegpm.org/tandem/thegpm_tandem.html) and calculated molecular weights of
possible metabolites were unsuccessful. This is not surprising because only a minor
fraction of a target protein is probably modified [27-29]. Thus, even if present, the
amount of a modified peptide may be lower than the instrumental limit of detection. If the
modification is fragile, it could undergo fragmentation in the electrospray-ms interface,
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resulting in loss of further structural analysis. However, this is unlikely as covalent
conjugates of both gluthathione-TA and mercaptoethanol-TA isomer metabolites were
successfully analysed by ESI-MS in earlier studies [12,16]. Nevertheless, it cannot be
excluded that modified peptides could be labile in the LC solvent resulting in loss of
adducts during separation, as proposed previously [11]. In summary, 15 proteins were
found to be covalently modified. Surprisingly, Cytochrome P450 2C11 was not identified
despite that the protein was previously reported to be modified by a reactive intermediary
of TA [13]. In this study, densiometric quantification of immuno blots showed maximum
modification to occur in rats 2-4 h after TA ingestion, followed by a steady decline until
36 h. The level of modification was approximately 20% of total after exposure for 24 h,
the delay time we used, before isolating the liver for 2D Western blotting and protein
identification. In addition, the conditions for immuno blotting were different because we
did not use any protein blocking reagents. Finally, we separated the proteins by 2D
electrophoresis using a method not especially optimized for membrane proteins, and
since CYP 2C11 likely is a membrane bound protein and therefore notoriously more
difficult to handle, it may well have escaped detection. Three proteins identified, which
include selenium binding protein, disulfide isomerase and Hsc73, have been shown to be
common targets for other reactive drug intermediates and chemicals in previous studies.
Selenium binding protein 2 was previously found to be covalently modified by the
reactive intermediary N-acetyl-p-benzoquinone, a metabolite of acetaminophen [30,31],
metabolites of chemicals like  3'-hydroxyacetanilide [32] and bromobenzene [33]. The
function of selenium binding protein is presently unknown but it has been suggested to
function as a scavenger protein involved in the cellular defence mechanism [31]. In
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contrast, the protein was recently shown to increase acetaminophen toxicity when over
expressed in COS-1 cells, and thus, this subject is still controversial [34]. Because
disulphide isomerase is an abundant protein involved in redox state control it is critical
for maintaining apt cellular homeostasis. This protein catalyzes the rearrangement of
disulphide bonds. Thus, the toxicological consequence(s) of a reactive TA intermediary
may depend on the extent of modification and potential malfunction of disulphide
isomerase. Similarly, this protein seems to be a common target for various reactive
intermediaries including mycophenolic acid [21], naphthalene [25], halothane [35],
bromobenzene [36], monocrotaline [37]. The dnaK-type molecular chaperone Hsc73,
also called Hsc70 or Hspa8, was previously shown to be adducted by a reactive
intermediary of naphthalene [25]. To our knowledge, the remaining 12 proteins identified
have not previously been identified as targets for other reactive metabolites. Several of
these proteins are enzymes that participle in metabolic (adenosine kinase,
fumarylacetoacetase, ketohexokinase, triosephosphate isomerase, malate dehydrogenase)
and catabolic (arginase) cellular processes. Capping protein (actin filament) is part of the
cytoskeleton, whereas two proteins (senescence marker protein and superoxide
dismutase) may be involved in cellular defence mechanisms. Adenosylhomocysteinase is
thought to play a role in methylation via the regulation of adenosylhomocysteine. Finally,
two of the targets are enzymes implicated in the cellular salvage of proteins (proteasome
endopeptidase  complex) and N-terminal blocked amino acids (Acy1). Future studies are
required to evaluate if modification and/or collective inhibition of these enzymes either
entirely or partly may cause cellular stress that together with implication of the immune
18
system could explain the mechanism involved in TA adverse reactions. This will entail
the development of approaches to determine quantitatively ratio of modified versus
unmodified target proteins and the consequential toxicological impact when this ratio is
displaced.
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Table I. Proteins identified in fraction I.
    Mowse   peptides
spot
a
Protein ID
Mr
weight
b pI
b
score Assigned
c
1 Q5U3X3_RAT  Albumin 70710 6,1 337 14
 Q5BKB4_RAT  Hemopexin 52060 7,6 154 10
      
2 ABRTS       serum albumin precursor 70670 6,1 692 26
 Q5BKB4_RAT  Hemopexin 52060 7,6 163 9
      
3 ABRTS       serum albumin precursor 70670 6,1 219 14
 S21089      alpha-1-microglobulin/inter-alpha-trypsin inhibitor light chain 39738 5,8 196 8
  Q66HD0_RAT  Tumor rejection antigen gp96 (Predicted) 74390 5 50 2
      
4 AAH62393    BC062393 NID protein disulfide isomerase associated 3 57044 5.9 877 30
 ABRTS       serum albumin precursor 70670 6,1 236 12
      
5 ABRTS       serum albumin precursor 68674 6,1 262 7
 Q8VIF7_RAT  Selenium binding protein 2 53069 6,1 171 8
 ABRTS       serum albumin precursor 70670 6,1 115 6
  AAF43598    AF170918 NID 54530 6,6 95 3
      
6 Q8VIF7_RAT  Selenium binding protein 2 53069 6,1 270 9
 AAF43598 4-trimethylaminobutyraldehyde dehydrogenase 54530 6,6 131 7
 Q5XIM9_RAT  Chaperonin containing TCP1, subunit 2 (Beta).- 57764 6 90 4
      
7 Q6AYS7_RAT  Acy1 protein 46060 6 186 13
      
8 A49098      N-hydroxyarylamine sulfotransferase, HAST-I 35855 6,1 83 6
 MDHC_RAT    Malate dehydrogenase, cytoplasmic (EC 1.1.1.37) 36500 6,2 36 3
      
9 S27881    beta-alanine synthase 44584 6,5 146 9
 1D3VA     arginase (EC 3.5.3.1), chain A 33423 6,6 61 2
      
10 S27881      beta-alanine synthase 44584 6,5 317 14
 JH0467      fumarylacetoacetase (EC 3.7.1.2) 33423 6,6 212 7
 A54756      isocitrate dehydrogenase (NADP) (EC 1.1.1.42), 47047 6,5 79 3
 AJRTQ       glutamate-ammonia ligase (EC 6.3.1.2) 42982 6,6 49 3
 Q2IBC6_RAT  Caveolin 1 20710 5,7 35 2
      
11  1D3VA       arginase (EC 3.5.3.1), chain A - rat 33423 6,6 219 8
 S15835      3-oxo-5beta-steroid 4-dehydrogenase (EC 1.3.99.6) - rat 37639 6,2 176 10
 PPID_RAT    40 kDa peptidyl-prolyl cis-trans isomerase (EC 5.2.1.8) 41008 6,7 128 5
      
12 Q5EBB4_RAT  Haptoglobin.- Rattus norvegicus 39052 6,1 312 14
 Q497B0_RAT  Nitrilase family, member 2 31024 6,9 45 3
      
13 GBLP_BOVIN  Guanine nucleotide-binding protein subunit beta 2-like 1 35380 7,6 306 11
22
 Q6AZ06_RAT  Betaine-homocysteine methyltransferase.- Rattus norvegicus 45421 8 213 9
 GSTM1_RAT   Glutathione S-transferase Mu 1 (EC 2.5.1.18) 25937 8,4 173 8
 GNMT_RAT    Glycine N-methyltransferase (EC 2.1.1.20) 32796 7,2 118 5
 JU0133      translation elongation factor eEF-1 alpha chain - Chinese hamster 50424 9,1 80 4
 DERTMM      malate dehydrogenase (EC 1.1.1.37) precursor, mitochondrial 36089 9,2 64 2
 Q66HT1_RAT  Aldob protein.- Rattus norvegicus 39956 8,7 59 4
 JC5884      thyroid hormone sulfotransferase (EC 2.8.2.-) B1 35041 8,2 56 2
 AAF14047    AF021854 NID:  - Rattus norvegicus 32698 8,9 49 2
 ADH1_RAT    Alcohol dehydrogenase 1 (EC 1.1.1.1) 40401 8,5 48 3
  Q7TMC7_RAT  Ab2-417 (Cc1-8).- 109510 8,4 46 3
      
14 Q66HT1_RAT  Aldob protein 39956 8,7 368 17
 Q6AZ06_RAT  Betaine-homocysteine methyltransferase 45421 8 225 9
 RTRS      argininosuccinate synthase (EC 6.3.4.5) 46752 7,3 136 11
  PGK1_RAT    Phosphoglycerate kinase 1 (EC 2.7.2.3).- 44794 7,5 91 8
 ADH1_RAT    Alcohol dehydrogenase 1 (EC 1.1.1.1) 40401 8,5 89 6
 Q5M916_RAT  Glyceraldehyde-3-phosphate dehydrogenase 36056 8,1 69 4
 Q9EQS4_RAT  Cystathionine gamma-lyase (CTL target antigen).- 44236 7,4 46 2
      
15 JX0230      proteasome endopeptidase complex (EC 3.4.25.1) iota chain 27838 6,3 171 6
 GSTM1_RAT   Glutathione S-transferase Mu 1 (EC 2.5.1.18) (GSTM1-1) 25937 8,4 55 3
   TPIS_RAT    Triosephosphate isomerase (EC 5.3.1.1) (TIM) 27286 6,5 55 3
 1AFSA       3alpha-hydroxysteroid dehydrogenase (EC 1.1.1.50),     
      
16 PDIA6_RAT   Protein disulfide-isomerase A6 precursor (EC 5.3.4.1) 48542 5 174 6
 
Q6TUG0_RAT  LRRGT00084 (DnaJ (Hsp40) homolog, subfamily B, member
11) 40755 5,9 134 7
      
17 Q66HT1_RAT  Aldob protein.- Rattus norvegicus (Rat). 39956 8,7 425 18
 ADH1_RAT    Alcohol dehydrogenase 1 (EC 1.1.1.1) 40401 8,5 74 4
 Q6P9U7_RAT  Ldha protein 30041 9,2 76 7
 DERTG  glyceraldehyde-3-phosphate dehydrogenase (EC 1.2.1.12) 36098 8,4 70 5
 DERTMM      malate dehydrogenase (EC 1.1.1.37) 36089 8,9 58 2
 HAOX2_RAT   Hydroxyacid oxidase 2 (EC 1.1.3.15) (HAOX2) 39502 7,9 54 2
 1D3VA       arginase (EC 3.5.3.1), chain A 33423 6,6 43 2
 DHB4_RAT    Peroxisomal multifunctional enzyme type 2 (MFE-2) 79760 8,8 41 2
      
18 Q5RKK4_RAT  Sec31l1 protein.- Rattus norvegicus (Rat). 117889 7,3 139 5
 Q5U3X3_RAT  Albumin.- Rattus norvegicus 70710 6,1 93 5
      
19 1D3VA  arginase (EC 3.5.3.1), chain A 35122 6,6 114 7
 1AFSA  3alpha-hydroxysteroid dehydrogenase (EC 1.1.1.50), chain A 37172 7,5 54 2
      
20 Q9Z0V5_RAT    PRx IV (Peroxiredoxin 4).- 31216 6,2 119 5
 Q4VAE6_MOUSE  Ras homolog gene family, member A 22110 5,8 97 3
 ATP5H_RAT     ATP synthase D chain, mitochondrial (EC 3.6.3.14).- 18678 6,2 63 4
 AAH85750 lysophospholipase 1 25034 6,1 59 3
 Q6Q288_RAT    Mitochondrial aldehyde dehydrogenase (Fragment).- 56078 7,6 38 2
      
21 BAA09695  RATER60P NID: 57010 5,9 96 5
 TERA_RAT  Transitional endoplasmic reticulum ATPase (TER ATPase) 89846 5,1 42 2
23
      
22 Q5U3X3_RAT  Albumin.- Rattus norvegicus (Rat). 70710 6,1 382 13
 Q642G1_RAT  Adenosine kinase.- Rattus norvegicus 40449 5,8 230 11
 Q6Q289_RAT  Mitochondrial aldehyde dehydrogenase (Fragment).- 56078 7,6 130 7
 A28807      protein disulfide-isomerase (EC 5.3.4.1) 57044 6,4 103 6
 AAF43598    4-trimethylaminobutyraldehyde dehydrogenase 54530 6,6 68 3
      
23 Q5BKB7_RAT  Ftcd protein 59504 5,8 649 24
 AAH62393 protein disulfide isomerase associated 3 57044 5,9 400 17
 ABRTS       serum albumin precursor 70670 6,1 45 2
      
24 Q3T1K5_RAT  Capping protein (Actin filament) 33118 5,6 120 4
a. Spots are from the India ink stained 2D immuno-blot shown in figure 3A.
b. Molecular weight and isoelectric point was obtained from the Mascot search engine.
c. Number of peptides assigned to the protein entry.
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Table II. Proteins identified in fraction II.
    Mowse   peptides
spot
a
Protein ID
Mr
weight
b
pI
b
score assigned
c
1 JC4853      dnaK-type molecular chaperone hsc73 - mouse 71055 5,4 289 11
 Q5BKB4_RAT  Hemopexin.- Rattus norvegicus (Rat). 52060 7,6 134 10
 Q5U3X3_RAT  Albumin.- Rattus norvegicus 70710 6,1 119 5
 Q6IMF3_RAT  Type II keratin Kb1.- Rattus norvegicus 65190 8 55 3
2 Q5U3X3_RAT  Albumin.- 70710 6,1 373 14
 JC4853      dnaK-type molecular chaperone hsc73 - mouse 71055 5,4 118 6
 Q5BKB4_RAT  Hemopexin.-  52060 7,6 49 4
      
3 Q5U3X3_RAT  Albumin.- Rattus norvegicus 70710 6,1 256 8
      
4 AAH62393  protein disulfide isomerase associated 3 57044 5,9 371 16
 Q5U3X3_RAT  Albumin.- 70710 6,1 309 14
 AAF43598    AF170918 NID 54530 6,6 68 2
      
5 AAF43598 4-trimethylaminobutyraldehyde dehydrogenase 54530 6,6 115 4
 A28807      protein disulfide-isomerase (EC 5.3.4.1) 57044 6,4 112 6
 Q5BKB7_RAT  Ftcd protein 59504 5,8 66 3
      
6 ENOA_RAT    Alpha-enolase (EC 4.2.1.11) 46967 6,2 191 8
 Q8VIF7_RAT  Selenium binding protein 2.- 52498 6,1 187 8
 AAF43598    AF170918 NID: 53618 6,6 163 5
 Q5XIM9_RAT  Chaperonin containing TCP1, subunit 2 (Beta).- 57422 6 137 6
      
7 ATCHB   actin beta - chicken 42052 5,3 173 6
      
8  Q6AYS7_RAT  Acy1 protein.- Rattus norvegicus (Rat). 46060 6 163 8
      
9 S34588      senescence marker protein SMP-30 33938 5,4 134 4
      
10 R5RT10    acidic ribosomal protein P0, cytosolic [similarity] 34350 5,9 107 3
 MDHC_RAT  Malate dehydrogenase, cytoplasmic (EC 1.1.1.37) 36500 6,2 68 2
      
11 SAHH_RAT      Adenosylhomocysteinase (EC 3.3.1.1) 47889 6,1 348 12
 Q5XID2_RAT    TAR DNA binding protein (Predicted).- 32526 6,5 59 4
      
12 Q5BKC2_RAT  Endoplasmic retuclum protein 29 28614 6,2 76 4
 S40468      proteasome subunit RC10-Ii 23235 6,2 70 3
      
13 S32426  ketohexokinase (EC 2.7.1.3) 33299 6,2 465 14
      
14 JX0230  proteasome endopeptidase complex (EC 3.4.25.1) 27838 6,3 274 9
      
25
15 TPIS_RAT  Triosephosphate isomerase (EC 5.3.1.1) (TIM) 27286 6,5 85 3
      
16 HPPD_RAT  4-hydroxyphenylpyruvate dioxygenase (EC 1.13.11.27) 45181 6,3 217 10
      
17 S27881  beta-alanine synthase 44584 6,5 247 11
 JH0467  fumarylacetoacetase (EC 3.7.1.2) 46231 6,7 42 2
      
18 1AFSA       3alpha-hydroxysteroid dehydrogenase (EC 1.1.1.50), 37172 7,3 202 7
 Q6IMF3_RAT  Type II keratin Kb1.- Rattus norvegicus (Rat). 65190 8 139 4
      
19 SODC_RAT  Superoxide dismutase [Cu-Zn] (EC 1.15.1.1).- 15492 5,9 281 8
      
20
CAH3_RAT    Carbonic anhydrase 3 (EC 4.2.1.1) (Carbonic anhydrase
III) 29567 7 196 10
 JC1132      phosphoglycerate mutase (EC 5.4.2.1) B chain 28928 6,7 100 5
 Q4V8M8_RAT  Hagh protein (Fragment).- Rattus norvegicus 34036 7,8 87 5
 TPIS_RAT    Triosephosphate isomerase (EC 5.3.1.1) 27286 6,5 40 2
      
21 PSA2_RAT    Proteasome subunit alpha type 2 (EC 3.4.25.1) 25893 7,1 270 9
 
GSTM2_RAT   Glutathione S-transferase Mu 2 (EC 2.5.1.18) (GSTM2-
2) 25726 7,3 105 4
      
22 TPIS_RAT    Triosephosphate isomerase (EC 5.3.1.1) 27286 6,5 82 3
 Q6IMF3_RAT  Type II keratin Kb1.- Rattus norvegicus     
      
23 Q4V8I9_RAT  UDP-glucose pyrophosphorylase 2.- 57159 7,2 67 3
      
24 GSTM1_RAT   Glutathione S-transferase Mu 1 (EC 2.5.1.18) 25937 8,4 117 4
 Q6IMF3_RAT  Type II keratin Kb1.- Rattus norvegicus 65190 8 110 4
 Q6IFU8_RAT  Type I keratin KA17.- Rattus norvegicus (Rat). 48378 5 78 3
  K2C8_RAT    Keratin, type II cytoskeletal 8 (Cytokeratin-8) 53854 5,8 78 3
a. Spots are from the India ink stained 2D immuno-blot shown in figure 3C.
b. Molecular weight and isoelectric point was obtained from the Mascot search engine.
c. Number of peptides assigned to the protein entry.
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Table III. Proteins identified in fraction III.
    Mowse  peptides
spot
a
Protein ID
Mr
weight
b
pI
b
score assigned
c
1 GRP75_R Stress-70 protein 74086 6 460 12
 JC4853 dnaK-type molecular chaperone hsc73 71055 5,4 255 10
      
2 Q8VIF7_RAT  Selenium binding protein 2 53069 6,1 92 7
      
3 Q642G1_RAT  Adenosine kinase.- Rattus norvegicus (Rat). 40449 5,8 146 5
      
4 ENOA_RAT    Alpha-enolase (EC 4.2.1.11) 47309 6,2 238 9
 SAHH_RAT    Adenosylhomocysteinase (EC 3.3.1.1) 47889 6,1 107 5
 S06114      methionine adenosyltransferase (EC 2.5.1.6) 44240 5,6 51 3
      
5
MDHC_RAT  Malate dehydrogenase, cytoplasmic (EC
1.1.1.37) 36500 6,2 198 11
a. Spots are from the India ink stained 2D immuno-blot shown in figure 3E.
b. Molecular weight and isoelectric point was obtained from the Mascot search engine.
c. Number of peptides assigned to the protein entry.
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Table IV. Proteins identified in fraction IV.
    Mowse peptides
spot
a
Protein ID
Mr
weight
b
pI
b
score assigned
c
1 Q9JKB7_RAT  Guanine deaminase 51439 5,5 47 3
 I59346      glutathione synthase (EC 6.3.2.3 52597 5,5 47 2
      
2 DOPD_D-dopachrome decarboxylase (EC 4.1.1.84) 13108 6,2 208 9
 RJRTO       retinol-binding protein, cellular 15995 5,1 84 2
 FABPB_Fatty acid-binding protein, brain (B-FABP) 15008 5,5 71 3
      
3 Q5U3X3_RAT  Albumin.- 70710 6,1 396 15
 Q5BKB4_RAT  Hemopexin.-  52060 7,6 110 7
      
4 Q6IMF3_RAT  Type II keratin Kb1.- Rattus norvegicus 65190 8 131 5
      
5 ABRTS       serum albumin precursor 70670 6,1 831 31
     
6 Q5U3X3_RAT  Albumin 70710 6,1 100 2
 
DDAH1_NG,NG-dimethylarginine
dimethylaminohydrolase1(EC3.5.3.18) 31674 5,8 95 3
      
7 Q8VIF7_RAT  Selenium binding protein 2 53069 6,1 197 9
 AAF43598    AF170918 NID 54530 6,6 193 8
 ENOA_RAT    Alpha-enolase (EC 4.2.1.11) 47309 6,2 106 6
 ABRTS       serum albumin precursor 70670 6,1 104 3
 Q6Q288_RAT  Mitochondrial aldehyde dehydrogenase (Fragment).- 56078 7,6 90 3
      
8 Q642G1_RAT  Adenosine kinase.- Rattus norvegicus (Rat). 40449 5,8 365 18
      
9 Q5U3X3_RAT  Albumin.- Rattus norvegicus 70710 6,1 198 5
 Q6Q290_RAT  Mitochondrial aldehyde dehydrogenase (Fragment).- 56051 6,4 65 5
 A28807 Protein disulfide-isomerase 57010 5,9 54 4
     
10 Q6AYS7_RAT  Acy1 protein.- Rattus norvegicus (Rat). 46060 6 301 16
 SAHH_RAT    Adenosylhomocysteinase (EC 3.3.1.1) 47889 6,1 203 6
 AAF43598    AF170918 NID 54530 6,6 152 7
      
11 SAHH_RAT      Adenosylhomocysteinase (EC 3.3.1.1) 47889 6,1 675 26
 HPPD_RAT 4-hydroxyphenylpyruvate dioxygenase (EC 1.13.11.27) 45181 6,3 51 5
      
12 HPPD_RAT 4-hydroxyphenylpyruvate dioxygenase (EC 1.13.11.27) 45181 6,3 452 22
 S27881      beta-alanine synthase 44584 6,5 112 6
 AAL61609    AF393243 NID: 41771 6,2 156 7
 JH0467      fumarylacetoacetase (EC 3.7.1.2) 46231 6,7 110 5
 Q68FT9_RAT  Selenocysteine lyase 47682 6,2 104 4
 SAHH_RAT    Adenosylhomocysteinase (EC 3.3.1.1) 47889 6,1 62 3
      
28
13 JH0467      fumarylacetoacetase (EC 3.7.1.2) 46231 6,7 188 9
a. Spots are from the India ink stained 2D immuno-blot shown in figure 3G.
b. Molecular weight and isoelectric point was obtained from the Mascot search engine.
c. Number of peptides assigned to the protein entry
Table V. Identified protein targets likely to be modified by
reactive intermediates of TA.
Protein ID
Mr
weight
a
pI
a
Selenium binding protein 2 53069 6,1
senescence marker protein SMP-30 33938 5,4
Adenosin kinase 40449 5,8
Acy1 protein 46060 6,0
Adenosylhomocysteinase 47889 6,1
Capping protein (Actin filament) 33118 5,6
ENOA_RAT    Alpha-enolase (EC 4.2.1.11) 47309 6,2
Fumarylacetoacetase 33423 6,6
Arginase chain A 35122 6,6
Ketohexokinase 33299 6,2
Proteasome endopeptidase complex 27838 6,3
Triosephosphate isomerase 27286 6,5
Superoxide dismutase 15492 5,9
Malate dehydrogenase 36500 6,2
a. Molecular weight and isoelectric point was obtained from the
Mascot search program.
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